Unione Europea -
italiano -
EMA (European Medicines Agency)
xtandi
astellas pharma europe b.v. - enzalutamide - neoplasie prostatiche - terapia endocrina - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
xtandi 40 mg capsule molli
astellas pharma ag - enzalutamidum - capsule molli - enzalutamidum 40 mg, antiox.: e 320, e 321, excipiens per la capsula. - prostatico - synthetika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
xtandi 40 mg compresse rivestite con film
astellas pharma ag - enzalutamidum - compresse rivestite con film - enzalutamidum 40 mg, hypromellosi acetas succinas, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 3 mg, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - prostatico - synthetika
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
xtandi 80 mg compresse rivestite con film
astellas pharma ag - enzalutamidum - compresse rivestite con film - enzalutamidum 80 mg, hypromellosi acetas succinas, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 6 mg, magnesii stearas, Überzug: hypromellosum, talcum, macrogolum 8000, e 171, e 172 (flavum), pro compresso obducto. - prostatico - synthetika